Novartis AG, Global Alliance For TB Drug Development Link Up To Search For TB Cure
Novartis Provides Drug Candidate Compounds To TB Alliance Exclusive Worldwide License From Novartis Includes A Novel Class Of Drugs That Is Active Against Drug Sensitive And Multi-Resistant Strains Of Tuberculosis Basel, August 20, 2014 - Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development ... (more)
Tue Aug 19, 2014
Why Novartis (NVS) Stock Is Gaining Today
Under the agreement, Novartis would immediately invest $35 million in Gamida for the stake and receive an option to fully acquire the company, according to parent company Elbit Imaging STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.
Mon Aug 18, 2014
Bio IT World
Could Pharma Companies Succeed in the Digital Health Market?
Jason Bloomberg speaks to pharma executives and industry observers who believe top drug companies could soon focus more of their efforts on creating electronic health platforms, collecting user data and to more precisely define disease risks and personalize prevention and treatment.
Deal Is Back On: Novartis AG To Invest Heavily In Gamida Cell Ltd. Before Acquisition
The deal for the sale of Gamida Cell developer of a stem-cell treatment for blood cancer, to Novartis AG is back on.
Wed Aug 13, 2014
Drug Patent Expirations This Week: Pfizer's Nicotine Spray, Transdermal Hormones
One patent relates to Novartis/Noven/Novogyne's CombiPatch, as well as two other transdermal hormone therapies for postmenopausal women.
Novartis AG, Siemens, And Laboratory Corporation of America Holdings...
Seventh Sense Biosystems Closes $16 Million Series B Financing CAMBRIDGE, Mass., Aug 13, 2014 -- Seventh Sense Biosystems, Inc. , the pioneering developer of virtually painless blood collection and diagnostic platforms, today announced a $16 million Series B financing from a syndicate of global leaders in diagnostic technologies, pharmaceuticals ... (more)
Mon Aug 11, 2014
Sunshine Heart C-Pulse: A Paradigm Shift In Heart Failure Therapy
Only Sunshine Heart's C-Pulse has achieved a significant reversal of Heart Failure in 60% of its FDA approved Feasibility Trial NYHA Class III and ambulatory Class IV heart failure patients.
Partnership between Google and Novartis to create a 'smart' contact lens
'Smart' contact lenses that are capable of monitoring glucose levels in Diabetes sufferers, and potentially restoring the natural autofocus in people who wear glasses, could soon become a reality thanks to a partnership between Google and Novartis.
Sanofi Appears To Be In The Early Stages Of An Earnings Rebound
Sanofi , the subject of this article, is one of the oldest and largest pharmaceutical concerns in the world, competing in the same league as world-class enterprises Novartis , Pfizer , Glaxo , and Merck .
Wed Aug 06, 2014
Chosen to Manage Global SAP Infrastructure for Leading Swiss Healthcare Company
ZURICH / BASEL, Switzerland - 06 Aug 2014: IBM today announced that it signed a multi-year agreement with Novartis, one of the world's leading healthcare companies, to manage their global SAP infrastructure operations.
Tue Aug 05, 2014
Momenta Pharmaceuticals Heading For A Repeat
While most promising young biotechs devote all resources to development of new drugs, Momenta Pharmaceuticals is adopting a fairly unusual strategy of aiming for the middle.
Fri Aug 01, 2014
Novartis AG Malaria Pill KAE609 Shows Promise As Best Drugs Fail
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years KAE609 was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections For more than a decade, Novartis ... (more)
Thu Jul 31, 2014
Novartis: Ten Years of Solid ROE
In this article, letA s see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the Return on Equity , and we are going to analyze it in the case of Novartis AG .
Good Value Johnson & Johnson Could Outperform This Peer
In this article we're focusing on Johnson & Johnson and comparing it to a similar sized rival in Novartis .
VGK, GULF: Big ETF Outflows
Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF , where 2,699,946 units were destroyed, or a 1.0% decrease week over week.
Wed Jul 30, 2014
Novartis: The Case Of The Undervalued Biosimilar Pioneer
Most investors, specially when they start looking at this sector, find themselves overwhelmed with information and technical jargon.
Tue Jul 29, 2014
Ziopharm Joins The CAR Crowd
The kinetics of the rheoswitch do not appear to be compatible with the needs of physicians who administer CAR T cell therapy.
Mon Jul 28, 2014
Why Pfizer Will Trade At $40 On Improved Drug Pipeline
Pfizer is trading at a P/E that is almost 30 points below Merck , 13 points below Novartis and 15 point below Sanofi .
VEA, AZIA: Big ETF Inflows
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF , which added 7,502,706 units, or a 1.3% increase week over week.
Google Smart Lenses May Treat and Detect Illness
Novartis and Google have partnered to develop a contact lens with the potential for a wide array of medical and lifestyle uses.